Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

Jahr

2020

Autoren

Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.

Verlag

Mult Scler. 2020 Jan;26(1):48-56.

Link

https://doi.org/10.1177/1352458518816612

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study